Study wrapper · #840
Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists.
Editor's note
This large real-world cohort speaks directly to a well-publicized worry: whether semaglutide and tirzepatide carry neuropsychiatric risk, including depression and suicidal ideation. Drawing on a federated network of over 192 million patients with propensity-matched, new-user designs (85,546 pairs for tirzepatide vs semaglutide; 80,115 for semaglutide vs other GLP-1 RAs), researchers found the two tracked peptides had comparable psychiatric risk over two years, with only a small, cautiously-flagged Year-2 anxiety signal for tirzepatide. Semaglutide was associated with lower rates of depression, anxiety, and suicidal ideation than earlier-generation GLP-1 RAs. Both peptides are central. The caveats are real: this is observational, so residual confounding by indication and channeling (who gets prescribed what) can bias comparisons; coded diagnoses undercount psychiatric events; and the tirzepatide-vs-other-GLP-1 comparison isn't shown. Reassuring as a signal against a heightened neuropsychiatric hazard, but not a substitute for randomized safety adjudication. Weight it as supportive real-world evidence, appropriately hedged.
Plain-language abstract
Reports have raised concern that newer weight and diabetes drugs might affect mental health, including depression and suicidal thoughts. This study used a huge database of over 192 million patients to compare mental-health outcomes among adults with type 2 diabetes and/or obesity who newly started tirzepatide, semaglutide, or older GLP-1 drugs between 2022 and 2025. To make comparisons fair, researchers matched patients on many characteristics and followed them for up to two years. Tirzepatide and semaglutide showed similar rates of depression, anxiety, and suicidal thinking, with only a small possible increase in anxiety for tirzepatide in the second year that the authors said should be viewed cautiously. Semaglutide was linked to lower rates of these psychiatric problems than older GLP-1 drugs. Important limits: because this observed real-world care rather than a randomized trial, differences in who gets prescribed each drug could influence the results, and mental-health conditions recorded in medical codes may be undercounted. Overall the findings are reassuring but not definitive.